Atrasentan in Patients With Proteinuric Glomerular Diseases (NCT04573920)

🧪 Interventions in This Study

• Atrasentan (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (33 Sites)

Showing the first 25 of 33 sites.

• Kidney Disease Medical Group — Glendale, California
• Academic Medical Research Institute — Los Angeles, California
• North America Research Institute — San Dimas, California
• Stanford U School Of Medicine — Stanford, California
• Colorado Kidney Care Nephrology — Denver, Colorado
• Northwest Louisiana Nephrology Research — Shreveport, Louisiana
• Tufts Medical Center — Boston, Massachusetts
• Uni of Minnesota Hos and Clinics — Minneapolis, Minnesota
• DaVita Clinical Research — Las Vegas, Nevada
• Mountain Kidney And Hyper Associa — Asheville, North Carolina
• Brookview Hills Research Assoc — Winston-Salem, North Carolina
• Baylor Scott and White — Dallas, Texas
• Prolato Clinical Research Center — Houston, Texas
• Milwaukee Nephrologists SC — Wauwatosa, Wisconsin
• Novartis Investigative Site — Gosford, New South Wales
• Novartis Investigative Site — Herston, Queensland
• Novartis Investigative Site — Clayton, Victoria
• Novartis Investigative Site — Reservoir, Victoria
• Novartis Investigative Site — St Albans, Victoria
• Novartis Investigative Site — St Leonards,
• Novartis Investigative Site — Roma, RM
• Novartis Investigative Site — Cheonan, Chungcheongnam-do
• Novartis Investigative Site — Anyang-si, Gyeonggi-do
• Novartis Investigative Site — Seoul, Korea
• Novartis Investigative Site — Seoul,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in IgA Nephropathy

• A Study of Zigakibart in Adults With IgA Nephropathy — Birmingham, Alabama
• Atrasentan in Patients With IgA Nephropathy — Birmingham, Alabama
• Atacicept in Subjects With IgA Nephropathy — Brisbane, California
• A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G — Lawrenceville, Georgia
• Study of BHV-1400 in IgA Nephropathy — Farmington, Connecticut

Explore by condition: All IgA Nephropathy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.